Technology | July 08, 2008

FDA Clears Angiotech’s 5-FU Central Venous Catheter

Angiotech Pharmaceuticals Inc. received 510(k) clearance from the FDA to market its 5-Fluorouracil (5-FU) coated central venous catheter (CVC).

The 5-FU CVC is the first drug-eluting medical device to be researched and developed completely in-house by Angiotech's research and development department. The company said it will be a stepping stone for development of other implantable devices that utilize the same proprietary anti-infective technology.

The clinical data from Angiotech's 960 patient clinical trial
comparing its 5-FU CVC with a chlorhexidine/silver sulfadiazine (CH-SS)-coated CVC was recently presented by clinical investigators at the 28th International Symposium on Intensive Care and Emergency Medicine in Brussels. There were no occurrences of clinically evident bloodstream infection in patients treated with Angiotech's 5-FU CVC, the company said.


Additional Content

News | Catheters

Nov. 4, 2026 — Evident Vascular has announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Evident ...

Home November 05, 2026
Home
News | Catheters

Sept. 14, 2026 — Interventional Medical Device Solutions (IMDS), has announced the U.S. launch of NHanceIT, an over-the ...

Home September 15, 2026
Home
News | Catheters

June 30, 2026 — Penumbra Inc. has received the CE Mark for Red 72 Silver Label and Red 72 Silver Label with SENDit ...

Home July 02, 2026
Home
News | Catheters

Feb. 12, 2026 – CellProthera has acquired the transendocardial catheter originally developed by Celyad Oncology. This ...

Home February 12, 2026
Home
News | Catheters

Oct. 23, 2025— Emboline, Inc., a provider of full-body embolic protection devices for transcatheter procedures, thas ...

Home October 28, 2025
Home
Subscribe Now